Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. - Test2 - elhamkhani - TriplyDB

Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.

Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.

http://www.wikidata.org/entity/Q30596414

about

Novel approaches to identify protective malaria vaccine candidates Vaccines for the 21st century Revealing the sequence and resulting cellular morphology of receptor-ligand interactions during Plasmodium falciparum invasion of erythrocytes Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites The interaction between seasonality and pulsed interventions against malaria in their effects on the reproduction number IMPIPS: the immune protection-inducing protein structure concept in the search for steric-electron and topochemical principles for complete fully-protective chemically synthesised vaccine development Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data.Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial Cost-effectiveness analysis of vaccinating children in Malawi with RTS,S vaccines in comparison with long-lasting insecticide-treated nets.How advances in immunology provide insight into improving vaccine efficacy.A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine.Memory B-cell and antibody responses induced by Plasmodium falciparum sporozoite immunization.The repeat region of the circumsporozoite protein is critical for sporozoite formation and maturation in Plasmodium.Plasmodium falciparum UvrD activities are downregulated by DNA-interacting compounds and its dsRNA inhibits malaria parasite growth Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.Impact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection.Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine design Breadth of humoral response and antigenic targets of sporozoite-inhibitory antibodies associated with sterile protection induced by controlled human malaria infection Human newborn bacille Calmette-Guérin vaccination and risk of tuberculosis disease: a case-control study.The Power of Malaria Vaccine Trials Using Controlled Human Malaria Infection.Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults.Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.A mathematical model of the impact of present and future malaria vaccines Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.Antibody responses to a novel Plasmodium falciparum merozoite surface protein vaccine correlate with protection against experimental malaria infection in Aotus monkeys.Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.Immunity to malaria in an era of declining malaria transmission.Whole Pichia pastoris yeast expressing measles virus nucleoprotein as a production and delivery system to multimerize Plasmodium antigens.Malaria vaccines: past, present and future.A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice.Identification of Protective B-Cell Epitopes within the Novel Malaria Vaccine Candidate Plasmodium falciparum Schizont Egress Antigen 1.malERA: An updated research agenda for combination interventions and modelling in malaria elimination and eradication.Improving DNA vaccines against malaria: could immunization by gene gun be the answer?The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination.Induction of immunity following vaccination with a chemically attenuated malaria vaccine correlates with persistent antigenic stimulation.Le vaccin antipaludique RTS,S/AS01 chez les enfants âgés de 5 à 17 mois au moment de la première vaccination

P2860

Q21131082-E52644FC-9816-4786-BD62-A52A32996D7A Q27007529-BB3C3E5C-F811-4473-BCCF-168B68F883D2 Q27321307-2221E403-9C43-4492-8688-4FF99F0E0968 Q28541281-57D7660D-D07D-409B-81AE-3351C6D83FEA Q28543031-FD9725D2-CD42-423B-929C-54D334EDE235 Q30373743-BBCA71AF-B9DA-43F7-8B3A-703E29E99515 Q30662529-3479513F-86E6-4859-BBF6-84A7F477B317 Q30991737-FF076B23-A3B9-4536-9881-9CEB1609D39E Q33590453-5669F8A9-1CBB-4F9C-9E47-A199DB04BAEF Q33896995-F8F6A3AB-7C17-4081-96AF-598F1EECB307 Q34487139-4B6042DD-A2AC-44E2-A0F6-676E9762CD7F Q34563555-9654B4F7-721B-486C-A564-58D30E723952 Q34600916-AFD0170D-DC67-4FAD-8FDD-33CFCA42FD4A Q35140796-BACB4297-12C2-4E66-A23B-96B6420FEECE Q35163318-297C22F8-597D-4469-957A-A533FE5B6E4A Q35439859-F75E0DCE-452C-4C3B-81F2-D638F2C541B7 Q35887367-79D0FA6E-49D4-4B0F-AD57-4EEE18334A1C Q36004060-24206733-0370-4739-ADA7-AC63A720681C Q36018901-6F96191B-A6BA-4B06-89F3-32209C8C5744 Q36247418-AD9B64D0-7334-4342-BADB-427135E48B3E Q36393102-0E06875D-53B6-4F54-8EEA-92417AF35774 Q36466129-B48D46D3-2622-4A6A-9E89-6DB003C15FBE Q36858852-5D1B4725-451C-43B5-9EC3-491385F7CAB6 Q37161928-09711518-4D01-4E0A-8FB0-4BFE635E4894 Q37452080-DCA1CBB2-8B17-44B5-B891-0830FB6601B7 Q38599514-E7B8A2E0-DE50-4E2A-AEEF-FA636ACEEC9F Q38689264-EE35660F-E02C-4364-A96C-43F401FAB9F6 Q39261291-00FA054C-0466-469B-BD2C-3ABA69112F3B Q39345614-8E3E29AE-0BE2-4623-9A85-307A31BFC0D7 Q40210139-EF5CB4AC-697F-4D16-A1EE-7DF2DF5C69B9 Q40227597-C29B81B9-DA85-49AC-A570-6A5A4B11C1F7 Q47132201-C6C85F42-257B-4996-BDF6-F1D042C9D544 Q47831305-695B296E-C128-4683-A1A8-2FCD5E952F24 Q47977891-46137722-E960-4440-88C3-A8BC19A7866D Q55403419-FF51662E-FC21-4C0A-8C11-CE34AACDE76F Q58131059-9403DF9B-3EA5-4941-B4D3-9BB11824F76B

P2860

Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.

http://www.wikidata.org/entity/Q30596414

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Efficacy of RTS,S malaria vacc ...... oled analysis of phase 2 data.

@ast

Efficacy of RTS,S malaria vacc ...... oled analysis of phase 2 data.

@en

type

label

Efficacy of RTS,S malaria vacc ...... oled analysis of phase 2 data.

@ast

Efficacy of RTS,S malaria vacc ...... oled analysis of phase 2 data.

@en

prefLabel

Efficacy of RTS,S malaria vacc ...... oled analysis of phase 2 data.

@ast

Efficacy of RTS,S malaria vacc ...... oled analysis of phase 2 data.

@en

P1433

Q30596414-DA4B1B1D-3219-410A-A9EF-89FAA8FEC524

P1476

Q30596414-A50E884C-E3D5-4906-B419-A091293436E7

P2093

Q30596414-01DDAB20-344D-46EB-AC7F-BA09967ECB4A

Q30596414-23CA6D78-6EE5-4828-A746-2577B5CCF179

Q30596414-264F93F9-C2B4-4EE7-BDEA-9FE55D479CAF

Q30596414-33527862-C4FB-4F8A-817D-531FD85F4C5D

Q30596414-3D800BB9-00BC-4014-89EA-AB1A1D0E020C

Q30596414-7EF2D8B3-C583-4E13-B927-5E22BEB4D275

P2860

Q30596414-05BE7A0C-7F78-49A5-8128-4E0D101F45A2

Q30596414-17D3FEFC-59B1-46AD-A94C-54C0639DB86D

Q30596414-191432A0-E5B7-4F3C-8AEA-3EA2CE691D50

Q30596414-23A06E53-9B6F-45D9-A5F9-89AE1821EF5A

Q30596414-23B72C84-E680-463C-9CB7-537BA2A17021

Q30596414-32777258-785F-4844-937B-1F61B06D7878

Q30596414-42935F8A-312F-4B88-819D-93B71AFBDB84

Q30596414-5F548A3F-27F0-4E26-BF14-B475E1F95C1C

Q30596414-682E07B8-8884-4E88-AC4D-D18112DCE200

Q30596414-7EA244A9-39D6-4EE9-9A9D-12D29FE2D2D8

P304

Q30596414-11B81A72-4456-460B-B37E-25EFC5504805

P31

Q30596414-6CBDDF6F-F529-40C8-80E3-DCEF609AD0DA

Q30596414-a681577d-71e1-4aa3-a5eb-d5a6fd0e0376

P356

Q30596414-B4AE8F68-BA51-4F14-AC71-92A22079DA15

P433

Q30596414-2F86902C-9B4E-41C7-B0AB-3316DB620E04

P478

Q30596414-C426C3CE-2C53-4248-B8E0-800993F303B8

P50

Q30596414-03DAC557-260F-46FD-960F-7EB0B721FBF9

Q30596414-0640DFA8-5599-4DAD-A4B9-50C51A3ACBDD

Q30596414-163389C8-12DB-49BD-AB95-132EA7B55BC3

Q30596414-4317DFE1-5E0F-4C78-BBAB-93125C0263AD

Q30596414-81BECC91-9FD4-495A-B56A-AE4489793B08

Q30596414-A29DD6E7-26C6-43B3-AD13-5479CE170DFB

P577

Q30596414-11C95CEA-CAFC-4412-BC7E-1886EA31551C

P698

Q30596414-E597A824-1281-4370-9F57-9D3C2D9E3B6D

P921

Q30596414-092DF78E-DB4E-48AC-B26C-7FE2362F2F2B

P932

Q30596414-94C5E425-E227-4F3E-9DC8-2E9C65D012D6

P356

S1473-3099(13)70005-7

P1433

The Lancet Infectious Diseases

P1476

Efficacy of RTS,S malaria vacc ...... oled analysis of phase 2 data.

@en

P2093

Ally Olotu

http://www.w3.org/2001/XMLSchema#string

John P A Lusingu

http://www.w3.org/2001/XMLSchema#string

Kwaku Poku Asante

http://www.w3.org/2001/XMLSchema#string

Nahya Salim

http://www.w3.org/2001/XMLSchema#string

Nekoye N Otsyula

http://www.w3.org/2001/XMLSchema#string

Selidji T Agnandji

http://www.w3.org/2001/XMLSchema#string

P2860

A world malaria map: Plasmodium falciparum endemicity in 2007

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children.

Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.

Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data.

Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya.

Defining clinical malaria: the specificity and incidence of endpoints from active and passive surveillance of children in rural Kenya.

Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.

P304

319-327

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1473-3099(13)70005-7

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Kalifa A Bojang

Seth Owusu-Agyei

Michael T White

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23454164

http://www.w3.org/2001/XMLSchema#string

P921

P932

3771416

http://www.w3.org/2001/XMLSchema#string